|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 参附注射液急重症临床应用专家共识显示文摘参附注射液是由红参、附片提取制成的中药注射剂,1987年获得上市许可,应用于临床已有30余年历史,临床上被广泛用于休克、心肺复苏、心力衰竭等急危重症,列为《国家基本医疗保险、工伤保险和生育保险药品目录》甲类品种。上市后再评价研究表明,参附注射液安全性高,并且具有良好的卫生经济学效益。因此,参附注射液被《中国严重脓毒症/脓毒性休克治疗指南》、《心肺复苏与中西医结合急救指南》、《急性心肌梗死中医临床诊疗指南》、《慢性心力衰竭中西医结合诊疗专家共识》等多个国内指南和共识推荐. | 中国医师协会急诊医师分会 中国研究型医院学会休克与脓毒症专业委员会 赵晓东 张新超 姚咏明 于学忠 周荣斌 | 2018 | 临床急诊杂志2018，19，10： | 33 |
| 2 | 参附注射液治疗心脑血管疾病相关物质基础及作用机制研究进展显示文摘参附注射液(Shenfu injection,SFI)的主要有效成分为人参皂苷和乌头类生物碱,具有回阳救逆、益气固脱之功效,广泛用于心脑血管疾病的治疗。慢性炎症是心脑血管疾病发生的关键因素。SFI作为治疗心脑血管疾病的常用中药制剂,具有改善脏器灌注、保护心肌和脑缺血时组织损伤、改善血流动力学、舒张血管等作用,而且具有确切的抗炎效应。该文基于抗炎角度,对SFI治疗心脑血管疾病相关物质基础及作用机制进行综述,可为SFI的临床应用提供参考。 | 李艳 陈雨 杨柳 吴瑞玉 严小军 聂鹏 姜丽 | 2019 | 中药新药与临床药理2019，30，4： | 20 |
| 3 | Traditional Chinese medicine in COVID-19显示文摘COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2(SARSCo V-2)has spread across the globe,posing an enormous threat to public health and safety.Traditional Chinese medicine(TCM),in combination with Western medicine(WM),has made important and lasting contributions in the battle against COVID-19.In this review,updated clinical effects and potential mechanisms of TCM,presented in newly recognized three distinct phases of the disease,are summarized and discussed.By integrating the available clinical and preclinical evidence,the efficacies and underlying mechanisms of TCM on COVID-19,including the highly recommended three Chinese patent medicines and three Chinese medicine formulas,are described in a panorama.We hope that this comprehensive review not only provides a reference for health care professionals and the public to recognize the significant contributions of TCM for COVID-19,but also serves as an evidence-based in-depth summary and analysis to facilitate understanding the true scientific value of TCM. | Ming Lyu Guanwei Fan Guangxu Xiao Taiyi Wang Dong Xu Jie Gao Shaoqin Ge Qingling Li Yuling Ma Han Zhang Jigang Wang Yuanlu Cui Junhua Zhang Yan Zhu Boli Zhang | 2021 | Acta Pharmaceutica Sinica B2021，11，11： | 14 |
| 4 | Shenfu injection attenuates lipopolysaccharide-induced myocardial inflammation and apoptosis in rats显示文摘Shenfu injection(SFI), a Chinese medicinal product, shows potent efficacy in treating sepsis. The aim of the present study was to clarify the protective effects of SFI against lipopolysaccharide(LPS)-induced myocardial inflammation and apoptosis.Experiments were carried out in Sprague-Dawley(SD) rats treated with LPS or LPS + SFI, and in H9 C2 cardiomyocytes. The sepsisassociated myocardial inflammation and apoptosis was induced by the intraperitoneal injection of LPS(20 mg·kg–1). SFI attenuated the increased expression of tumor necrosis factor(TNF)-α and interleukin(IL)-1β induced by LPS both in serum and heart. In LPS group,cell viability was reduced, and reversed after SFI administration. LPS treatment increased the expression levels of cleaved-caspase 3 and Bax, and those of Bcl2 and Bcl2/Bax. These two trends were reversed by SFI administration. The expression levels of phosphorylated mitogen-activated protein kinase kinase(p-MEK) and phosphorylated extracellular regulated protein kinases(p-ERK) were increased by LPS, and reversed by SFI. MEK inhibitor U0126 attenuated the apoptosis induced by LPS. These results indicate that SFI could treat LPS-induced cardiac dysfunction. In conclusion, SFI attenuates the inflammation and apoptosis induced by LPS via downregulating the MEK and ERK signaling pathways. | CHEN Rui-Juan RUI Qing-Lin WANG Qiong TIAN Fang WU Jian KONG Xiang-Qing | 2020 | Chinese Journal of Natural Medicines2020，18，3： | 12 |
| 5 | 参附注射液急重症临床应用专家共识显示文摘参附注射液是由红参、附片提取制成的中药注射剂,1987年获得上市许可,应用于临床已经有30余年历史,广泛应用于休克、心肺复苏、心力衰竭等急危重症,列为《国家基本医疗保险、工伤保险和生育保险药品目录》甲类品种。上市后再评价研究表明,参附注射液安全性高,并且具有良好的卫生经济学效益。 | 中国医师协会急诊医师分会 中国研究型医院学会休克与脓毒症专业委员会 | 2018 | 中国急救医学2018，38，11： | 11 |
| 6 | 参附注射液在危重症患者中的应用进展显示文摘参附注射液是我国传统医学和现代医学融合发展的结晶,随着近些年对其作用机制的不断探索及临床研究的逐渐深入,其适用范围不断拓展,尤其在救治急危重症患者中的有效性和安全性不断得到肯定,日益受到学者们的关注。本文就参附注射液的作用机制以及在危重症患者,特别是休克及心肺复苏患者中的应用进行综述,以期对将来基础医学和临床研究有所帮助。 | 司向 管向东 | 2020 | 中华重症医学电子杂志2020，6，1： | 11 |
| 7 | Effect of Shen-Fu Injection(参附注射液)on Hemodynamics in Early Volume Resuscitation Treated Septic Shock Patients显示文摘Objective: To investigate the hemodynamic effect of Shen-Fu Injection(参附注射液, SFI) in early volume resuscitation treated septic shock patients by monitoring pulse indicator continuous cardiac output(PICCO). Methods: All septic shock patients admitted in the Intensive Care Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from January 1 st, 2014 to December 31 th, 2015, were reviewed, and totally 65 were enrolled in this study. They were assigned to SFI group(33 cases) and control group(32 cases). All 65 patients underwent conventional treatment mainly including volume resuscitation, antibiotics and vasoactive drugs therapy. The patients of the SFI group received additional 100 mL of SFI intravenously every 12 h. In all 65 patients, the PICCO arterial catheter and vein catheter were implanted within 1 h after the diagnosis of septic shock. In the course of early volume resuscitation, hemodynamic data of patients were recorded by PICCO monitor at 0, 12, and 24 h after the catheter implantation. Results: The hemodynamic indices of the two groups showed no significant differences at the beginning of 0 h(P>0.05). At 12 and 24 h, the hemodynamic indices of SFI group were significantly improved in comparison with the control group(P<0.05), including cardiac index(CI), global end diastolic volume index(GEDI), mean arterial pressure(MAP) and heart rate(HR). In addition, there was no significant change of extra-vascular lung water index between the two groups(P>0.05). Conclusion: SFI significantly improved hemodynamic indices such as CI, GEDI, MAP and HR in early volume resuscitation treated septic shock patients. | FAN Kai-liang WANG Jun-hui KONG Li ZHANG Fei-hu HAO Hao ZHAO Hao TIAN Zheng-yun YIN Ming-xin FANG Hua YANG Hui-hui LIU Yang | 2019 | Chinese Journal of Integrative Medicine2019，25，1： | 10 |
| 8 | 参附注射液联合依诺肝素钠治疗急性心肌梗死并心力衰竭的疗效分析显示文摘目的探讨参附注射液联合依诺肝素钠治疗急性心肌梗死并心力衰竭的疗效。方法选择2016年8月-2018年5月铜川市人民医院治疗的334例急性心肌梗死并心力衰竭患者作为研究对象,随机将其分为观察组(174例)与对照组(160例)。对照组患者使用注射用依诺肝素钠,75岁以下患者起始静脉负荷30 mg,之后每12 h皮下注射1 mg/kg;75岁以上患者直接每12 h皮下注射0.75 mg/kg。观察组在对照组的基础上静脉滴注参附注射液40 mL,1次/d。两组均连续治疗10 d后评价疗效。比较两组的心肌酶谱、超声心动图检查、血浆氨基末端前体脑钠肽(NT-proBNP)、内皮素-1(ET-1)改善情况及30 d内的主要心脏事件(MACE)和出血并发症发生情况。结果治疗后,两组天冬氨酸氨基转移酶(AST)、肌酸激酶MB同工酶(CK-MB)、α-羟丁酸脱氢酶(α-HBDH)均显著下降(P<0.05),观察组显著低于对照组(P<0.05)。治疗后,两组LVEF显著升高,LVDd均明显降低(P<0.05),而对照组CO、E/A无明显改善,观察组以上指标均显著优于对照组(P<0.05)。治疗后,两组血浆NT-proBNP、ET-1水平均显著下降(P<0.05),观察组下降显著优于对照组(P<0.05)。观察组MACE发生率显著低于对照组(P<0.05)。两组出血并发症比较无统计学意义。结论急性心肌梗死并心力衰竭使用依诺肝素钠抗凝出血并发症少,安全性高,同时加用参附注射液可显著改善心肌酶谱,改善左心室功能,提高预后。 | 冯军鹏 梁梅芳 王有恒 闫伟 | 2019 | 药物评价研究2019，42，10： | 9 |
| 9 | 参附注射液对氧化应激血管内皮损伤及相关信号转导通路的影响显示文摘目的研究参附注射液对氧化应激血管内皮损伤的作用及相关信号转导通路的影响。方法培养血管内皮细胞ECV304,MTT法筛选H_(2)O_(2)造模和参附注射液的干预浓度;DCFH-DA荧光探针检测细胞内活性氧(ROS)含量;Hoechst染色和流式细胞术检测评估细胞凋亡;Western blot法检测Cleaved Caspase-3、ERK、p-ERK、Bcl-2和Bax蛋白的表达。结果H_(2)O_(2)呈浓度依赖性诱导ECV304细胞死亡;H_(2)O_(2)促进ECV304细胞内ROS含量增加,参附注射液或N-乙酰半胱氨酸(NAC)可拮抗此过程;与对照组比较,H_(2)O_(2)能够诱导ECV304细胞凋亡,增加ERK和Caspase-3的活化,下调Bcl-2/Bax表达;与模型组比较,参附注射液或NAC能拮抗H_(2)O_(2)诱导的ECV304细胞凋亡,抑制ERK与Caspase-3的活化,上调Bcl-2/Bax表达(P<0.05)。结论参附注射液通过抑制ERK磷酸化和Caspase-3活化,上调Bcl-2/Bax表达,拮抗H_(2)O_(2)诱导的ECV304细胞凋亡。 | 陈瑞娟 吴坚 田芳 孔祥清 芮庆林 | 2021 | 南京中医药大学学报2021，37，4： | 7 |
| 10 | 参附注射液治疗脓毒症休克的疗效分析显示文摘目的探讨应用无创心排量检测仪(NICOM)观察参附注射液治疗脓毒症休克效果。方法选取2018年3月—2019年4月南京中医药大学南通附属医院院脓毒症休克重症患者23例行常规治疗,包括抗生素治疗、液体复苏、生命支持等,并在此基础上给予参附注射液治疗。观察患者治疗前后血流动力学参数[平均动脉压(MAP)、心功能指数(CI)、每搏变异指数(SVV)、外周总阻力指数(TPRI)]的变化情况,并比较治疗前后血乳酸水平的差异。结果脓毒症休克患者给予参附注射液治疗,治疗前后MAP分别为78.0(68.5,85.5)mmHg、91.0(85.0,110.0)mmHg,治疗后水平升高(P<0.05);治疗前后CI分别为3.20(2.65,3.60)L/(min·m^(2))、2.80(2.50,3.60)L/(min·m^(2)),差异无统计学意义(P>0.05);治疗前后SVV分别为0.17(0.12,0.19)、0.14(0.11,0.18),治疗后水平降低(P<0.05);治疗前后TPRI分别为2078.0(1756.5,2320.5)、2732.0(2186.0,3274.5),治疗后水平升高(P<0.05);治疗前后血乳酸水平分别为2.60(2.00,3.35)mmol/L、1.70(1.10,2.20)mmol/L,治疗后水平下降(P<0.05)。结论参附注射液对脓毒症休克患者血流动力学及血乳酸水平有较好的改善作用,对脓毒症休克有一定的治疗作用。 | 刘亚军 王智兰 黄赟 全超 | 2021 | 中国现代医学杂志2021，31，19： | 7 |
| 11 | 参附注射液对心源性休克动物模型心功能指标的影响及通过NF-κB通路的调控机制研究显示文摘目的探究参附注射液(Shenfu injection, SFI)对心源性休克(cardiogenic shock, CS)动物模型心功能指标的影响及通过调节核因子(nuclear factor, NF)-κB通路的机制研究。方法 36只大鼠随机分为Sham组、CS组、CS+SFI组,每组12只。CS组、CS+SFI组模拟体内CS模型,CS+SFI组大鼠使用SFI腹腔注射,剂量为10 mL·kg^(-1)。1周后,检测各组的心功能、心肌酶指标,HE染色检测心肌损伤情况。通过ELISA、RT-qPCR和Western Blot检测炎性因子以及NF-κB通路水平。通过免疫组化染色检测胶原蛋白1(collagen1,Col1)和Col3的水平。结果 3组间的各种指标比较差异显著(P<0.05)。其中CS组的LVESP、±dP/dt_(max)显著低于Sham组而LVEDP显著高于Sham组(P<0.05)。CS+SFI组的LVESP、±dP/dt_(max)显著高于CS组而LVEDP显著低于CS组(P<0.05)。CS组的LD[(3324.29±325.73) IU/L]和CK-MB[(1506.46±146.53) IU/L]显著高于Sham组[(1452.15±268.15) IU/L,(715.29±65.34) IU/L](P<0.05)。CS+SFI组的LD[(2587.48±294.46) IU/L]和CK-MB[(1005.48±124.61) IU/L]显著低于CS组(P<0.05)。CS组的IL-6[(19.46±3.47) pg/mL]和TNF-α[(16.45±2.34) pg/mL]显著高于Sham组[(6.95±1.58) pg/mL,(4.84±0.85) pg/mL](P<0.05)。CS+SFI组的IL-6[(12.89±2.84) pg/mL]和TNF-α[(11.50±2.12) pg/mL]显著低于CS组(P<0.05)。CS组的MyD88和NF-κB mRNA和蛋白水平显著高于Sham组(P<0.05)。CS+SFI组的MyD88和NF-κB mRNA和蛋白水平显著低于CS组(P<0.05)。CS组的Col1和Col3蛋白水平显著高于Sham组(P<0.05),CS+SFI组的Col1和Col3蛋白水平显著低于CS组(P<0.05)。结论 SFI中含有的活性成分可以通过抑制CS模型大鼠中的NF-κB通路的上调、抑制ECM累积和减少炎性因子的表达,从而缓解心肌损伤,保护心功能。 | 何志凌 招煦杰 谢雯雯 | 2021 | 中华中医药学刊2021，39，9： | 6 |
| 12 | 利用PiCCO技术观察参附注射液治疗难治性脓毒性休克的临床观察显示文摘目的利用PiCCO技术观察参附注射液在难治性脓毒性休克治疗过程中的临床疗效。方法患者14例采用随机数字表法随机分为对照组(常规治疗)与治疗组(常规治疗不佳后再联合参附注射液)各7例。连续治疗5d,通过PiCCO监测心指数(CI)、全心舒张末期容积指数(GEDI)、血管外肺水指数(ELWI)、全心射血分数(GEF)、平均动脉压(MAP)等各项指标的动态结果,统计呼吸机辅助通气时间、血管活性药物使用剂量及时间、乳酸水平的差异。结果经常规治疗后效果不佳,治疗组加用参附注射液,治疗后第1日PiCCO监测的各项指标无显著性差异(P>0.05)。治疗后第3日治疗组的MAP、GEDI、ELWI、SVRI、乳酸清除均优于对照组(P<0.05)。治疗后第5日,治疗组MAP高于对照组(P<0.05),治疗后治疗组CI、GEF、MAP、SVRI指标均优于对照组(P<0.05),而CVP、乳酸水平两组比较治疗组优于对照组(P<0.05)。治疗组总的血管活性药物使用剂量减少,使用时间缩短(P<0.05);呼吸机辅助通气时间缩短(P<0.05)。结论参附注射液在难治性脓毒性休克的治疗过程中具有一定的优势。 | 周玉玲 罗真春 刘坤 姚勇刚 | 2019 | 中国中医急症2019，28，6： | 6 |
| 13 | 参附注射液对心脑血管疾病防治作用的新进展显示文摘参附注射液(Shenfu injection,SFI)是通过现代技术提炼参附汤而成,主要含有红参和附子。本文将SFI防治心力衰竭、心肌缺血再灌注损伤、心律失常、心肌梗死、休克、冠心病、病毒性心肌炎、扩张性心肌病、心脏手术、脑血管疾病等心脑血管性疾病的相关研究机制进行综述,以了解SFI作用于心脑血管性疾病的防治机制,为临床应用提供更多的实验和理论依据。 | 苏湾英 洪芬芳 杨树龙 | 2018 | 南昌大学学报(医学版)2018，58，5： | 5 |
| 14 | Effect of Shenfu Injection(参附注射液)on Lactate and Lactate Clearance in Patients with Post-cardiac Arrest Syndrome:A Post Hoc Analysis of a Multicenter Randomized Controlled Trial显示文摘Objective: To assess the effects of Shenfu Injection(参附注射液, SFI) on blood lactate, and secondarily its effect on the lactate clearance(LC) in patients with post cardiac arrest syndrome(PCAS). Methods: The present study is a post hoc study of a randomized, assessor-blinded, controlled trial. Patients experienced in-hospital cardiac arrest between 2012 and 2015 were included in the predefined post hoc analyses. Of 1,022 patients enrolled, a total of 978 patients were allocated to the control group(486 cases) and SFI(492 cases) group, receiving standardized post-resuscitation care bundle(PRCB) treatment or PRCB combined with SFI(100 mL/d), respectively. Patients’ serum lactate was measured simutaneously with artery blood gas, lactate clearance(LC) was calculated on days 1, 3, and 7 after admission and compared between groups. Lactate and LC were also compared between the survivors and non-survivors according to the 28-d mortality, as well as the survivors and non-survivors subgroups both in the SFI and control groups. Results: In both groups, compared with pre-treatment levels, mean arterial pressure(MAP) and PaOwere significantly improved on 1, 3, 7 d after treatment(P<0.05), while heart rate(HR) and blood glucose levels were significantly decreased on 1, 3 and 7 d after treatment(P<0.05). compared with control group, SFI treatment improved the values of MAP and PaO(P<0.05), and significantly decreased the levels of HR and the blood glucose level on 3 and 7 d after treatment(P<0.05). Compared with the control group, lactate levels decreased faster in the SFI group versus the control group on 3 and 7 d(P<0.05). From initiation of treatment and the following 3 and 7 d, SFI treatment greatly increased the LC compared with that in the control group(P<0.05). Compared with survivors, non-survivors had higher admission lactate levels(7.3±1.1 mmol/L vs. 5.5±2.3 mmol/L;P <0.01), higher lactate levels on days 1, 3 and 7(P <0.05), and LC were decreased significantly on 3 and 7 d after treatment(P<0.05). Similar results were also found both in the SFI and control groups between survivors and non-survivors subgroups. Conclusion: SFI in combination with PRCB treatment is effective at lowering lactate level and resulted in increasing LC in a targeted population of PCAS patients. | HE Yong WANG Guo-xing LI Chuang WANG Yu-xing ZHANG Qian | 2022 | Chinese Journal of Integrative Medicine2022，28，10： | 3 |
| 15 | 参附注射液治疗血管性疾病机制研究进展显示文摘综述参附注射液治疗血管性疾病机制研究进展。参附注射液常用于血管性疾病的治疗,主要治疗机制:(1)心血管疾病方面涉及保护缺血再灌注损伤、调控心肌酶活性、调节心肌细胞电生理效应及离子通道、调节细胞因子;(2)脑血管疾病方面涉及保护神经、改善能量代谢、调节电生理和离子通道、调节细胞因子;(3)其他血管相关疾病涉及增加血管灌注,改变血流动力学和血液流变学以及保护血管内皮细胞。 | 苏湾英 洪芬芳 杨树龙 | 2018 | 上海中医药杂志2018，52，9： | 3 |
| 16 | Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data显示文摘Objective:To assess the trends in characteristics,treatments,and outcomes of acute myocardial infarction(AMI)patients in tertiary Chinese medicine(CM)hospitals in China between 2006 and 2013.Methods:This retrospective study was based on two nationwide epidemiological surveys of AMI in tertiary CM hospitals during 2 years(2006 and 2013).Patients admitted to the hospital for AMI were enrolled.Hospital records were used as the data source.Case data were derived regarding baseline characteristics,treatments,and outcomes of patients to assess changes from 2006 to 2013.Logistic regression was used to analyze the relationship between prognosis,general influencing factors of disease,and various treatment measures.Results:Totally 26 tertiary CM hospitals in 2006 and 29 tertiary CM hospitals in 2013(18 were repetitive)were surveyed.A total of 2,311 patients with AMI were enrolled(1,094 cases in 2006 and 1,217 cases in 2013).From 2006 to 2013,the mean age did not significantly change,but the proportion of patients younger than 65 years increased.The prevalence of risk factors such as hypertension,diabetes,and hyperlipidemia also increased.Significant increases were observed in primary percutaneous coronary intervention[20.48%(2006)vs.24.90%(2013)]and revascularization[36.11%(2006)vs.52.42%(2013)].In-hospital mortality decreased from 11.15%in 2006 to 10.60%in 2013.A mortality logistic regression analysis identified reperfusion therapy[odds ratio(OR),0.222;95%confidence interval(CI),0.106–0.464],Chinese patent medicines(OR,0.394;95%CI,0.213–0.727),and CM decoctions(OR,0.196;95%CI,0.109–0.353)as protective factors.Conclusion:Reperfusion and revascularization capabilities of tertiary CM hospitals have improved significantly,but in-hospital mortality has not significantly decreased.Efforts are needed to improve medical awareness of AMI and expand the use of CM to reduce in-hospital mortality in China. | LAI Xiao-lei LIU Hong-xu HU Xin TIAN Jing-feng SHANG Ju-ju LI Xiang ZHOU Qi XING Wen-long | 2021 | Chinese Journal of Integrative Medicine2021，27，5： | 2 |
| 17 | 参附注射液调节创伤性急性肺损伤肺血管内皮细胞功能的临床研究显示文摘目的通过参附注射液对创伤性急性肺损伤血管内皮细胞功能的研究,期望为创伤性急性肺损伤的治疗提供新的途径。方法将该院2016年6月—2018年6月收治的符合纳入标准的创伤性急性肺损伤患者80例,随机分为观察组(n=40)与对照组(n=40)。观察组为西药常规治疗加参附注射液组,给予5%葡萄糖注射液250mL+参附注射液50mL静滴,1次/d;对照组为西药常规治疗组。以上两组治疗均以7d为1个疗程,将治疗前后患者呼吸频率及实验室检查指标做观察比较。结果与对照组相比,观察组治疗后呼吸频率(22.50±3.56)次/min,优于对照组(t=2.27,P=0.029);PO2、PaO2/FiO2指标数据分别为(81.92±3.33)mmHg、(300.51±21.44),均优于对照组(t=2.144,2.328,P=0.038,0.025);ICAM-1、ET-1及NO分别为(12.98±2.41)ug/mL、(75.39±10.51)ng/mL、(28.18±5.7)ng/mL,均显著优于对照组(t=7.343,5.174,5.628,P=0.000);治疗后观察组总有效率77.5%明显高于对照组55.0%,两组比较,差异有统计学意义(χ^2=4.53,P<0.05)。结论参附注射液能明显改善创伤性急性肺损伤患者的呼吸频率,改善氧合指数,降低ICAM-l、ET-1、NO的水平,改善创伤性急性肺损伤患者的预后。 | 马民 曹斌 常秀云 李伟华 暴玉振 赵俊泉 吴玉成 | 2019 | 系统医学2019，4，10： | 1 |
| 18 | Efficacy of Renshen(Radix Ginseng) plus Fuzi(Radix Aconiti Lateralis Preparata) on myocardial infarction by enhancing autophagy in rats显示文摘OBJECTIVE:To elucidate the protective effects of Renshen(Radix Ginseng)and Fuzi(Radix Aconiti Lateralis Preparata)on myocardial infarction(MI)through regulating myocardial autophagy.METHODS:Thirty-one male Sprague-Dawley rats were randomized into five groups(n=6 or 7 for each).After treatment for 3 weeks,electrocardiogram(ECG)and cardiac function were recorded.Hematoxylin and eosin(HE)staining was used to detect pathological changes in the heart.Enzyme-linked immunosorbent assay(ELISA)was used to detect serum B-type brain natriuretic peptide(BNP),cardiac troponin T(c Tn T),tumor necrosis factor-α(TNF-α),and serum inflammatory cytokines.Metabolomic analysis was used to identify differential biomarkers of MI in rats.Immunohistochemistry and western blotting were used to detect BNP,cTnT,TNF-α,LC3B,Beclin-1,p62,and adenosine monophosphate activated protein kinase(AMPK)expression in cardiac tissue.RESULTS:Fuzi(Radix Aconiti Lateralis Preparata)alone or Renshen(Radix Ginseng)plus Fuzi(Radix Aconiti Lateralis Preparata)markedly ameliorated cardiac dysfunction and abnormal ECGs,demonstrated by decreases in the heart weight/body weight ratio,BNP,and c Tn T.Pro-inflammation cytokine interleukin(IL)-1αsignificantly decreased and anti-inflammatory cytokine IL-10 significantly increased in Renshen(Radix Ginseng)single or Renshen(Radix Ginseng)plus Fuzi(Radix Aconiti Lateralis Preparata)groups compared with the control group.HE results suggested that co-treatment produced a greater reduction in cardiomyocyte cross-sectional area than Renshen(Radix Ginseng)or Fuzi(Radix Aconiti Lateralis Preparata)alone.Renshen(Radix Ginseng)plus Fuzi(Radix Aconiti Lateralis Preparata)reversed these changes to different degrees in MI rats.Furthermore,Renshen(Radix Ginseng)plus Fuzi(Radix Aconiti Lateralis Preparata)down-regulated LC3 B,Beclin-1,and AMPK expression in cardiac tissue and upregulated p62 expression.CONCLUSIONS:Renshen(Radix Ginseng)plus Fuzi(Radix Aconiti Lateralis Preparata)may have a greater effect on heart injury induced by MI in rats than Fuzi(Radix Aconiti Lateralis Preparata)treatment alone,and the underlying mechanism may be associated with the regulation of myocardial autophagy and anti-inflammation effects.These results provide fresh insight into the mechanism of co-treatment with Renshen(Radix Ginseng)and Fuzi(Radix Aconiti Lateralis Preparata)for MI. | YANG Liang HUANG Guangyao WANG Yuguang HAN Baoqi ZHENG Bin ZHU Jinmiao GAO Shan GAO Yue | 2021 | Journal of Traditional Chinese Medicine2021，41，6： | 1 |
| 19 | Mechanism of'Invigorating Qi and Promoting Blood Circulation'Drug Pair Ginseng-Danshen on Treatment of Ischemic Heart Disease Based on Network Pharmacology显示文摘Objective:Using network pharmacology to explore the mechanism of the'invigorating qi and promoting blood circulation'drug pair Ginseng-Danshen(Salvia miltiorrhiza)on treatment of ischemic heart disease(IHD).Methods:The chemical constituents of ginseng and Danshen drug pair were identified by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and the potential targets of the pair were identified.The pharmacodynamics of the pair was analyzed using network pharmacology.The targets of IHD were identified by database screening.Using protein-protein interaction network,the interaction targets of Ginseng-Danshen on IHD were constructed.A'constituent-target-disease'interaction network was constructed using Cytoscape software,Gene Ontology(GO)term enrichment analysis and biological pathway enrichment analysis were carried out,and the mechanism of improving myocardial ischemia by the Ginseng-Danshen drug pair was investigated.Results:Seventeen active constituents and 53 targets were identified from ginseng,53 active constituents and 61 targets were identified from Danshen,and 32 protein targets were shared by ginseng and Danshen.Twenty GO terms were analyzed,including cytokine receptor binding,cytokine activity,heme binding,and antioxidant activity.Sixty Kyoto Encyclopedia of Genes and Genomes(KEGG)signaling pathways were analyzed,including phosphatidylinositol 3-kinase-serine-threonine kinase(PI3 K-AKT)signaling pathway,p53 signaling pathway,interleukin 17 signaling pathway,tumor necrosis factor signaling pathway,and the advanced glycation end product(AGE)-the receptor for AGE(RAGE)signaling pathway in diabetic complications.Conclusion:The specific mechanism of Ginseng-Danshen drug pair in treating IHD may be associated with improving the changes of metabolites inbody,inhibiting the production of peroxides,removing the endogenous oxygen free radicals,regulating the expression of inflammatory factors,reducing myocardial cell apoptosis and promoting vascular regeneration. | XIN Gao-jie ZHAO Yu-wei LI Ling-mei JIA Fei-fan HAN Xiao LI Lei GUO Hao MENG Hong-xu FU Jian-hua LIU Jian-xun | 2021 | Chinese Journal of Integrative Medicine2021，27，6： | 1 |
| 20 | 缺氧缺血性脑损伤新生大鼠胎盘生长因子的表达及参附注射液的干预作用显示文摘目的通过分析胎盘生长因子(PLGF)在缺氧缺血性新生大鼠病侧大脑表达,探讨其改善脑缺血、促进脑内血管再生以及参附注射液对新生大鼠缺氧缺血性脑损伤(HIBD)的保护作用。方法新生7 d SD大鼠随机分为三组:假手术组(S)、生理盐水对照组(C)、参附治疗组(SF)。按观察时间可依次分为6 h、12 h、1 d、3 d、7 d五个亚组,每个亚组8只。用Rice法制备新生大鼠HIBD模型。SF组在缺氧缺血性脑损伤后即刻以腹腔注射注射,其剂量为10 ml/kg,每日1次,连续3日同一时间点用药。C组则按照相同的注射方式及注射剂量,给予生理盐水。S组未给予药物治疗。其后以RT-PCR和免疫组织化学的方法检测大鼠右侧大脑皮层PLGF的表达变化。结果 S组各个时间点PLGF均有表达,无明显差异(P>0.05);C组在6 h时PLGF表达量开始增加,于1 d时达到高峰期,明显高于S组(P<0.05);SF组在6 h前PLGF表达量开始增加,整体表达趋势类似于C组,3 d时下降趋势更明显,但各时间表达量明显高于S组及C组(P<0.05)。结论缺氧缺血性脑损伤后,PLGF表达量明显增加,参附注射液能促进PLGF大量表达,对缺氧缺血性脑损伤后的新生大鼠起到保护作用。 | 杨倩倩 王军 徐艳 刘文强 | 2017 | 中国儿童保健杂志2017，25，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员